美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Inotek Pharmaceuticals Corporation

3.04

0.0000

成交量：- -

成交額：- -

市值：8,211.04萬

市盈率：-1.99

高：3.04

開：3.04

低：3.04

收：3.04

52周最高：3.80

52周最低：0.8500

股本：2,701.00萬

流通股本：1,206.00萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-1.5300

淨資產收益率：--

總資產收益率：--

市淨率：1.43

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Inotek Pharmaceuticals Corporation

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.inotekpharma.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Inotek製藥公司是於1999年7月7日根據美國特拉華州法律成立。該公司是一家臨床階段的生物製藥公司，專註於治療青光眼藥物的發現，開發和商業化。該公司領先的候選產品，trabodenoson，是一級可選擇的腺苷模擬，腺苷模擬是該公司通過恢複眼睛的自然壓力控制機制來降低眼壓機制。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ITEK/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ITEK","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ITEK\",,,,,undefined,":{"symbol":"ITEK","market":"US","secType":"STK","nameCN":"Inotek Pharmaceuticals Corporation","latestPrice":3.04,"timestamp":1515099600000,"preClose":3.04,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":12060000,"shares":27010000,"eps":-1.53,"marketStatus":"退市","change":0,"latestTime":"03-13 11:49:03 EDT","open":3.04,"high":3.04,"low":3.04,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.53,"tradingStatus":0,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1773432000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.04,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ITEK\",,,,,undefined,":{"symbol":"ITEK","floatShares":12060000,"roa":"--","roe":"--","lyrEps":0,"shares":27010000,"dividePrice":0,"high":3.04,"amplitude":0,"preClose":3.04,"low":3.04,"week52Low":0.85,"pbRate":"1.43","week52High":3.8,"institutionHeld":0,"latestPrice":3.04,"eps":-1.53,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.53,"open":3.04},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ITEK\",params:#limit:5,,,undefined,":[{"date":"2018-01-05","symbol":"ITEK","newSymbol":"RCKT","type":"symbolChange","dateTimestamp":1515128400000},{"market":"US","date":"2017-12-27","symbol":"ITEK","name":"Inotek Pharmaceuticals Corporation","time":"","type":"earning","dateTimestamp":1514350800000,"reportTimeType":""},{"market":"US","date":"2017-08-03","symbol":"ITEK","fiscalQuarterEnding":"2017/06","expectedEps":-0.54,"name":null,"time":"","type":"earning","dateTimestamp":1501732800000,"reportTimeType":"","actualEps":-0.24},{"market":"US","date":"2017-05-10","symbol":"ITEK","fiscalQuarterEnding":"2017/03","expectedEps":-0.35,"name":null,"time":"","type":"earning","dateTimestamp":1494388800000,"reportTimeType":"","actualEps":-0.4},{"market":"US","date":"2017-03-16","symbol":"ITEK","fiscalQuarterEnding":"2016/12","expectedEps":-0.39,"name":null,"time":"","type":"earning","dateTimestamp":1489636800000,"reportTimeType":"","actualEps":-0.48}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ITEK\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ITEK\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.inotekpharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0224},{"period":"1month","weight":-0.0377},{"period":"3month","weight":-0.023},{"period":"6month","weight":0.0132},{"period":"1year","weight":0.1918},{"period":"ytd","weight":-0.0233}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Inotek製藥公司是於1999年7月7日根據美國特拉華州法律成立。該公司是一家臨床階段的生物製藥公司，專註於治療青光眼藥物的發現，開發和商業化。該公司領先的候選產品，trabodenoson，是一級可選擇的腺苷模擬，腺苷模擬是該公司通過恢複眼睛的自然壓力控制機制來降低眼壓機制。","exchange":"NASDAQ","name":"Inotek Pharmaceuticals Corporation","nameEN":"Inotek Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ITEK\",market:\"US\",,,undefined,":null}}